En el primer ao, los pacientes tratados con 360 mg/da de orlistat perdieron un 10,2% del peso inicial, en comparacin con el 6,1% de prdida del grupo placebo (3,9 kg de diferencia, en promedio)
Month 3+: Continued weight loss, improved metabolic markers, and growing confidence in the medication
The strengths of this study include its large sample size with nationwide scope, rigorous target trial emulation framework, head-to-head comparisons with seven different types of anti-diabetic medications, including the first-generation of GLP-1RAs, clinically meaningful primary outcomes (first diagnosis of ADRD) complemented by secondary outcomes of dementia medication prescriptions
Pyruvate kinase M2 regulates Hif-1 activity and IL-1 induction and is a critical determinant of the warburg effect in LPS-activated macrophages